SEC EDGARSEP 11 min read$TEM

West Nadja sold $207K of TEM

West Nadja sold 3,000 shares of Tempus AI, Inc. (TEM) at $69.00 ($0.21M total) on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · West Nadja

Published Sep 1, 2026, 8:15 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 1, 2026, 8:46 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TEM

Bearish

medium confidence

Mentioned

$TEM

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TEMBearishLow

Why it matters

A director's sale of $207K is a routine disclosure with limited market impact, but it adds to the flow of insider activity data.

Market read

Minor insider sell; unlikely to move the stock significantly but worth noting for short‑term traders.

What to watch

The 10b5-1 plan pre‑arranges sales, reducing the informational value of the transaction.

Relevance 3/10Novelty 4/10Timing: post filing 2026-09-01

Background

SEC Form 4 filing discloses insider transactions. Tempus AI (TEM) is a health‑tech company listed on Nasdaq.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMBearishMedium confidence

Context

Director West Nadja sold 3,000 shares for $207,000 via a 10b5-1 plan, reducing holdings to 31,981 shares.

Expected impact

Potential short-term dip of 1‑2% as the market digests the sale.

Evidence & confidence

A director selling a modest stake under a pre‑arranged plan is a routine transaction, but any insider sell can prompt short‑term selling pressure.

Counterpoint

What could challenge this read

The sale may be purely portfolio rebalancing and not indicative of company fundamentals.

Key entities

company
Tempus AI, Inc.
Nasdaq‑listed health‑tech firm (ticker TEM).
person
West Nadja
Director of Tempus AI who sold shares.

Read at source ← All news

SEP 17

$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min

SEP 17

$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min

SEP 15

$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min

SEP 5

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min

SEP 2

$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min